Sheryar Siddiq
1 min read
In This Article:
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C. Wainwright reaffirmed its Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on June 23. The update comes after the American Diabetes Association (ADA) conference featured updated data from Vertex’s zimislecel program.
According to the clinical findings, 10 out of 12 patients, or 83% of the total, became insulin independent. Furthermore, as evidence of the treatment’s potential efficacy, H.C. Wainwright reported that all research participants achieved primary composite endpoints with sustained C-peptide restoration.
Notably, as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) seeks to expand its therapeutic areas, the zimislecel program represents a component of the company’s pipeline beyond its primary cystic fibrosis therapies.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that is involved in the discovery and development of small-molecule medications for the treatment of severe illnesses, including cystic fibrosis.
While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds
Disclosure: None.
